TRAVERE THERAPEUTICS, INC. (TVTX) Gross margin 2016–2025
TRAVERE THERAPEUTICS, INC. (TVTX) gross margin by fiscal year — reported gross profit divided by reported revenue.
97.9%FY2025 · since FY2016: 96.6% → 97.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 97.9% | +1.2 pp |
| FY2024 | 96.7% | +4.6 pp |
| FY2023 | 92.1% | -3.8 pp |
| FY2022 | 96.0% | -1.1 pp |
| FY2021 | 97.1% | +0.2 pp |
| FY2020 | 96.9% | -0.1 pp |
| FY2019 | 97.0% | +0.4 pp |
| FY2018 | 96.6% | -1.0 pp |
| FY2017 | 97.7% | +1.1 pp |
| FY2016 | 96.6% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TVTX financial trends
TVTX RevenueTVTX Net incomeTVTX Net marginTVTX Gross profitTVTX Operating incomeTVTX Operating marginTVTX Operating cash flowTVTX Free cash flowTVTX Capital expendituresTVTX Return on equityTVTX Stock buybacksTVTX Dividends paidTVTX Total assetsTVTX Total liabilitiesTVTX Shareholders’ equityTVTX overview →